Tests ruxolitinib with decitabine before stem cell transplant in leukemia
Tests added ruxolitinib and decitabine before transplant to lower leukemia relapse in high-risk patients.
Plain-language title generated from the registry record
Registry title: Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with acute myeloid leukemia in first complete remission who are going to have a stem cell transplant from a donor.
- Age
- The inclusion criteria say 12 to 64 years old. The registry fields list 14 to 75 years.
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia in first complete remission (CR1), with a reason for a donor stem cell transplant. Acute promyelocytic leukemia (M3) is excluded.
Main reasons for not taking part
- Acute promyelocytic leukemia (M3)
- Donor or patient is pregnant
- Infections that cannot be controlled
- Serious mental illness or conditions that prevent following the plan
- Liver or kidney tests above the limits set in the record
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 75 years old?
Source: NCT07101588, who can take part
Where in China
- Chinese PLA General HospitalBeijing, ChinaContact: Dai-hong Liu, Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT07101588
- Record updated
- 20 March 2026
- Original description
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.Read full original descriptionShow less
Ruxolitinib and Decitabine-Enhanced Conditioning Versus Modified Bu/Cy or BuF Conditioning for the Impact on Relapse of Acute Myeloid Leukemia in First Complete Remission (CR1)After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Prospective Randomized Controlled Trial
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.
Inclusion: 1) Acute myeloid leukemia with indications for allogeneic hematopoietic stem cell transplantation, CR1 2) Have HLA-matched sibling donors or haploidentical donors or ≥8/10 HLA-matched unrelated donors 3) The patients' ages range from 12 to 64 years old 4) Liver function: ALT and AST≤2.5 times the upper limit of normal values, bilirubin ≤2 times the upper limit of normal values 5) Renal function: Creatinine ≤ the upper limit of the normal value 6) There are no uncontrollable infections or serious mental and psychological disorders 7) Sign the informed consent form.
Exclusion: 1. Patients with acute promyelocytic leukemia (M3) 2. One of the donor and recipient is pregnant 3. Suffering from mental illness or other conditions that prevent one from following the plan.